NCT04188951View on ClinicalTrials.gov

HFHS-1801-A Pilot Study of Immunotherapy As Consolidation Therapy for Patients with Recurrent Head and Neck Cancer

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

October 4, 2019

Primary Completion Date

June 15, 2023

Study Completion Date

May 8, 2024

Conditions
Head and Neck Neoplasms
Interventions
DRUG

Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA]

Patients will receive 17 cycles of pembrolizumab via IV infusion of 200 mg over a period of 30 minutes, every 3 weeks starting no later than 90 days from the date of salvage head and neck therapy.

Trial Locations (1)

48202

Henry Ford Health System, Detroit

All Listed Sponsors
lead

Henry Ford Health System

OTHER

NCT04188951 - HFHS-1801-A Pilot Study of Immunotherapy As Consolidation Therapy for Patients with Recurrent Head and Neck Cancer | Biotech Hunter | Biotech Hunter